Memgen

Memgen is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer and infectious diseases like COVID-19. The company's pipeline includes MEM-288, an oncolytic virus developed in collaboration with Moffitt Cancer Center, designed to selectively target cancer cells while enhancing the immune response through the expression of proprietary immune modulators. This therapy aims to generate robust systemic anti-tumor immune responses following intra-tumoral vaccination across various cancer types. Additionally, Memgen is advancing its COVID-19 vaccine candidate, MemVax, which acts as an immune stimulant to be used alongside other COVID-19 vaccines, enhancing immune responses against the virus. With over 100,000 doses of MemVax prepared for clinical trials and an active application with the US FDA, Memgen is poised to initiate clinical testing for both MEM-288 in advanced cancers and MemVax in collaboration with other vaccine developers.